Methods and compositions for vaccinating a subject for a sexually transmitted pathogen
US-2017252424-A1 · Sep 7, 2017 · US
Chlamydia antigens
US9675683B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9675683-B2 |
| Application number | US-201514831535-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 20, 2015 |
| Priority date | Mar 6, 2009 |
| Publication date | Jun 13, 2017 |
| Grant date | Jun 13, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides Chlamydia antigens for use in the treatment, prevention and/or diagnosis of Chlamydia infection. In particular, the invention provides antigens CT733, CT153, CT601, CT279, CT443, CT372, CT456, CT381, CT255, CT341, CT716, CT745, CT387, CT812, CT869, CT166, CT175, CT163, CT214, CT721, CT127, CT043, CT823 and/or CT600 from C. trachomatis for the treatment, prevention or diagnosis of Chlamydia infection.
First claim
Opening claim text (preview).
The invention claimed is: 1. An immunogenic composition comprising an effective amount of: (a) an isolated Chlamydia CT372 antigen SEQ ID NO:12, an antigen with at least 95% sequence identity to SEQ ID NO: 12, or an antigen comprising the sequence of SEQ ID NO:74; (b) an isolated Chlamydia CT443 antigen SEQ ID NO:10, an antigen with at least 95% sequence identity to SEQ ID NO: 10, or an antigen comprising the sequence of SEQ ID NO:72; and c) a TH1 and/or TH2 adjuvant. 2. The immunogenic composition of claim 1 , wherein the antigens are in purified or substantially purified form. 3. The immunogenic composition of claim 1 , wherein the antigens are present as individual separate polypeptides. 4. The immunogenic composition of claim 1 , wherein the antigens are present as hybrid polypeptides. 5. A method of inducing an immune response in a subject, comprising administering an effective amount of the immunogenic composition of claim 1 to the subject.
Assignees
Inventors
Classifications
characterised by the dose, timing or administration schedule · CPC title
characterised by the type of response, e.g. Th1, Th2 · CPC title
Chlamydia · CPC title
Antibacterial agents · CPC title
against proteinaceous materials, e.g. enzymes, hormones, lymphokines · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9675683B2 cover?
- The invention provides Chlamydia antigens for use in the treatment, prevention and/or diagnosis of Chlamydia infection. In particular, the invention provides antigens CT733, CT153, CT601, CT279, CT443, CT372, CT456, CT381, CT255, CT341, CT716, CT745, CT387, CT812, CT869, CT166, CT175, CT163, CT214, CT721, CT127, CT043, CT823 and/or CT600 from C. trachomatis for the treatment, prevention or di…
- Who is the assignee on this patent?
- Glaxosmithkline Biologicals Sa, Glaxosmithkline Biologicals Sa
- What technology area does this patent fall under?
- Primary CPC classification A61K39/118. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 13 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).